Últimas noticias sobre Biodesix (NASDAQ:BDSX) Bolsa

Biodesix

Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.

Biodesix Inc

WIIM

ONCY

Oncolytics Biotech shares are trading higher after the company announced key progress and upcoming studies for breast and pancreatic cancer treatments while also preparing for an accelerated FDA approval path.

Fangdd shares are trading lower after the company announced a $5 million direct offering of 3.125 million shares at $1.60 per unit.

In the current market session, Lockheed Martin Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) stock price is at $605.14, after a 0.11% decrease. However, over the past month, the company's stock increased by 6.80%, and in the past year, by 38.63%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2024/1728069370_0.png" alt="Past Year Chart" />

<h3>How Does Lockheed Martin P/E Compare to Other Companies?</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 85.93 in the Aerospace &amp; Defense industry, Lockheed Martin Inc. has a lower P/E ratio of 21.99. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1728069370_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

News

Intraday Update

Markets

P/E Ratio Insights for Lockheed Martin

UBS analyst Dennis Geiger maintains Jack In The Box (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JACK#NASDAQ">JACK</a>) with a Neutral and lowers the price target from $55 to $50.

Price Target

Analyst Ratings

JACK

UBS Maintains Neutral on Jack In The Box, Lowers Price Target to $50

SAGE

Sage Therapeutics shares are trading lower after RBC Capital downgraded the stock from Sector Perform to Underperform and cut its price target from $10 to $4.

UBS analyst Kevin Caliendo maintains Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) with a Neutral and lowers the price target from $380 to $250.

UBS Maintains Neutral on Humana, Lowers Price Target to $250

EVGO

EVgo shares are trading higher after TD Cowen upgraded the stock from Hold to Buy and raised its price target from $5 to $7.

Citigroup analyst Christopher Allen maintains MarketAxess Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKTX#NASDAQ">MKTX</a>) with a Buy and raises the price target from $310 to $325.

MKTX

Citigroup Maintains Buy on MarketAxess Holdings, Raises Price Target to $325

Citigroup analyst Andrew Kaplowitz maintains Quanta Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PWR#NYSE">PWR</a>) with a Buy and raises the price target from $302 to $348.

Citigroup Maintains Buy on Quanta Services, Raises Price Target to $348

Marathon Digital Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARA#NASDAQ">MARA</a>) is trading higher Friday possibly on the back of positive news surrounding its Bitcoin mining operations and broader activity in the cryptocurrency sector. Here&#8217;s <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41140915/whats-going-on-with-bitcoin-mining-stock-marathon-digital-wednesday">what you need to know</a>.
What To Know: The company, one of the leading Bitcoin miners, released a production update this week, reporting a 5% increase in Bitcoin production for September, with a total of 705 Bitcoins mined compared to 673 in August. Additionally, Marathon holds a massive 26,842 Bitcoins, opting not to sell any in September.
Marathon's hash rate climed to 36.9 EH/s, up 5% month-over-month. The company is on track to meet its goal of reaching a hash rate of 50 EH/s by the end of 2024. Marathon also won 207 Bitcoin blocks last month, up 6% compared to August. These achievements reflect Marathon's focus on scaling its operations and optimizing its data centers, including the conversion of its Granbury data center to immersion cooling, which is progressing as planned.
The company's stock saw significant options activity, with both bullish and bearish positions being taken by large investors. While some expect the stock to fall in the $10 to $30 range in the coming months.
MARA Price Action: Marathon Digital shares were up by 5.53% at $16.33 at the time of writing, according to<a href="https://pro.benzinga.com/dashboard"> Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100424&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="1024" height="567" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/04143958/SOFI-1-1024x567.png" alt="" class="wp-image-581550" style="width:476px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/04143958/SOFI-1-1024x567.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/04143958/SOFI-1-300x166.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/04143958/SOFI-1-768x425.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/04143958/SOFI-1.png 1084w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
See Also:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41190083/us-labor-market-posts-strong-data-what-it-means-for-bitcoin">US Labor Market Posts Strong Data—What It Means For Bitcoin</a></li>
</ul>
Photo by JHVEPhoto via Shutterstock.

Movers

MARA

Marathon Digital Shares Weekly Recap: Strong Bitcoin Production and Increased Hash Rate Drive 5% Stock Surge

IRTC

iRhythm Technologies shares are trading lower. Goldman Sachs initiated coverage on the stock with a Neutral rating and announced a price target of $78.

Citigroup analyst Fatima Boolani maintains Zscaler (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) with a Buy and lowers the price target from $240 to $230.

Citigroup Maintains Buy on Zscaler, Lowers Price Target to $230

Abercrombie & Fitch shares are trading higher after JP Morgan maintained an Overweight rating on the stock and raised its price target from $194 to $195. Also, the stock is moving on continued strength following the dockworker strike tentative agreement.

Over the past 24 hours, Bittensor's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">TAO</a>) price rose 15.21% to $573.56. This continues its positive trend over the past week where it has experienced a 5.0% gain, moving from $535.76 to its current price. As it stands right now, the coin's all-time high is $757.60. 
The chart below compares the price movement and volatility for Bittensor over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1728068623_0.png" alt="price_chart" />
Bittensor's trading volume has climbed 16.0% over the past week, moving in tandem, directionally, with the overall circulating supply of the coin, which has increased 0.51%. This brings the circulating supply to 7.38 million, which makes up an estimated 35.15% of its max supply of 21.00 million. According to our data, the current market cap ranking for TAO is #28 at $4.23 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1728068623_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Trading Ideas

$TAO

Cryptocurrency Bittensor Rises More Than 15% In 24 hours

Citigroup analyst Jon Tower maintains Wingstop (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WING#NASDAQ">WING</a>) with a Neutral and raises the price target from $417 to $440.

WING

Citigroup Maintains Neutral on Wingstop, Raises Price Target to $440

Over the past 24 hours, Pepe's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PEPE</a>) price has risen 9.95% to $0.0000094. This is contrary to its negative trend over the past week where it has experienced a 12.0% loss, moving from $0.000011 to its current price.
The chart below compares the price movement and volatility for Pepe over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1728068554_0.png" alt="price_chart" />
The trading volume for the coin has tumbled 26.0% over the past week while the circulating supply of the coin has risen 0.35%. This brings the circulating supply to 420.69 trillion, which makes up an estimated 100.0% of its max supply of 420.69 trillion. According to our data, the current market cap ranking for PEPE is #31 at $3.96 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1728068554_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$PEPE

Cryptocurrency Pepe's Price Increased More Than 9% Within 24 hours

Cardano's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/ada/usd">ADA</a>) price has increased 4.49% over the past 24 hours to $0.35, which is in the opposite direction of its trend over the past week, where it has experienced a 13.0% loss, moving from $0.40 to its current price. As it stands right now, the coin's all-time high is $3.09. 
The chart below compares the price movement and volatility for Cardano over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1728068544_0.png" alt="price_chart" />
The trading volume for the coin has tumbled 29.0% over the past week while the circulating supply of the coin has risen 0.03%. This brings the circulating supply to 35.70 billion, which makes up an estimated 79.33% of its max supply of 45.00 billion. According to our data, the current market cap ranking for ADA is #12 at $12.61 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1728068544_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$ADA

Cardano Rises More Than 4% In 24 hours

In the preceding three months, 6 analysts have released ratings for Royal Gold (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGLD#NASDAQ">RGLD</a>), presenting a wide array of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $161.17, along with a high estimate of $175.00 and a low estimate of $141.00. Witnessing a positive shift, the current average has risen by 5.11% from the previous average price target of $153.33.
<img src="https://www.benzinga.com/files/images/story/2024/1728068544_0_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Royal Gold among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Murphy</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$154.00</td>
<td>$141.00</td>
</tr>
<tr>
<td>Tanya Jakusconek</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$157.00</td>
<td>$148.00</td>
</tr>
<tr>
<td>Brian MacArthur</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperformer</td>
<td>$170.00</td>
<td>$167.00</td>
</tr>
<tr>
<td>Matthew Murphy</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$141.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Anita Soni</td>
<td>CIBC</td>
<td>Raises</td>
<td>Neutral</td>
<td>$175.00</td>
<td>$166.00</td>
</tr>
<tr>
<td>Jackie Przybylowski</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$170.00</td>
<td>$168.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Royal Gold. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Royal Gold compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Royal Gold's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into Royal Gold's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/RGLD/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Royal Gold analyst ratings.</a>
<h2>Delving into Royal Gold's Background</h2>
Royal Gold Inc enquires and manages precious metal royalties and streams, with a focus on gold. The company operates by purchasing a percentage of the metal produced from a mineral property for an initial payment, without assuming responsibility of mining operations. Similarly, precious metal streams are purchase agreements with mine operators providing the right to purchase all or a portion of one or more metals produced from a mine, in exchange for an upfront deposit payment. Generally Royal Gold does not conduct any work on the properties in which it holds royalty and streaming assets. The company owns a portfolio of producing, development, evaluation, and exploration royalties and streams, and the majority of group revenue is generated from Canada, Mexico, Chile, and the United States.
<h3>Royal Gold: A Financial Overview</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Royal Gold's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 20.86%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Materials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Royal Gold's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 46.65% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Royal Gold's ROE excels beyond industry benchmarks, reaching 2.76%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Royal Gold's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.47% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.02.
<h2>The Significance of Analyst Ratings Explained</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

RGLD

Unveiling 6 Analyst Insights On Royal Gold

18 analysts have shared their evaluations of Charles Schwab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Charles Schwab, presenting an average target of $74.78, a high estimate of $90.00, and a low estimate of $64.00. A 5.41% drop is evident in the current average compared to the previous average price target of $79.06. 
<img src="https://www.benzinga.com/files/images/story/2024/1728068512_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Charles Schwab among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daniel Fannon</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$73.00</td>
<td>$79.00</td>
</tr>
<tr>
<td>Christopher Allen</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$72.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Alexander Blostein</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$67.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$70.00</td>
<td>-</td>
</tr>
<tr>
<td>Kyle Voigt</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$80.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$70.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Brian Bedell</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$80.00</td>
<td>$79.00</td>
</tr>
<tr>
<td>Patrick Moley</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$64.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Devin Ryan</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$82.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Kenneth Worthington</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$78.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$68.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Brian Bedell</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Buy</td>
<td>$79.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Craig Siegenthaler</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$66.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Bill Kirk</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$71.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$71.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$77.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Brennan Hawken</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$90.00</td>
<td>$91.00</td>
</tr>
<tr>
<td>Daniel Fannon</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$88.00</td>
<td>$85.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Charles Schwab. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Charles Schwab compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Charles Schwab's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Charles Schwab's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/SCHW/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Charles Schwab analyst ratings.</a>
<h2>Unveiling the Story Behind Charles Schwab</h2>
Charles Schwab operates in brokerage, wealth management, banking, and asset management. It runs a large network of brick-and-mortar brokerage branch offices and a well-established online investing website, and it has mobile trading capabilities. It also operates a bank and a proprietary asset-management business and offers services to independent investment advisors. Schwab is among the largest firms in the investment business, with over $8 trillion of client assets at the end of December 2023. Nearly all of its revenue is from the United States.
<h3>Charles Schwab: A Financial Overview</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Over the 3 months period, Charles Schwab showcased positive performance, achieving a revenue growth rate of 0.73% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Charles Schwab's net margin excels beyond industry benchmarks, reaching 25.82%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Charles Schwab's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 3.56%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Charles Schwab's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.26%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Charles Schwab's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.64.
<h2>What Are Analyst Ratings?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SCHW

A Glimpse Into The Expert Outlook On Charles Schwab Through 18 Analysts

Throughout the last three months, 7 analysts have evaluated Raymond James Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RJF#NYSE">RJF</a>), offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $130.71, with a high estimate of $138.00 and a low estimate of $123.00. This current average reflects an increase of 0.93% from the previous average price target of $129.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1728068488_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A clear picture of Raymond James Finl's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gerald O'Hara</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$126.00</td>
<td>$123.00</td>
</tr>
<tr>
<td>Alexander Blostein</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$125.00</td>
<td>$127.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Overweight</td>
<td>$138.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Cho</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$135.00</td>
<td>$137.00</td>
</tr>
<tr>
<td>Brennan Hawken</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$135.00</td>
<td>$138.00</td>
</tr>
<tr>
<td>Gerald O'Hara</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$123.00</td>
<td>$122.00</td>
</tr>
<tr>
<td>Bill Katz</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$133.00</td>
<td>$130.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Raymond James Finl. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Raymond James Finl compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Raymond James Finl's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Raymond James Finl's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/RJF/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Raymond James Finl analyst ratings.</a>
<h2>Unveiling the Story Behind Raymond James Finl</h2>
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company supports more than 8,000 employee and independent contractor financial advisors across the United States, Canada, and the United Kingdom with over $1.2 trillion of assets under administration as of September 2023. Approximately 90% of the company's revenue is from the US and 70% is from the company's wealth-management segment.
<h3>Unraveling the Financial Story of Raymond James Finl</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Raymond James Finl displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 10.92%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.
Net Margin: Raymond James Finl's net margin excels beyond industry benchmarks, reaching 15.41%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Raymond James Finl's ROE excels beyond industry benchmarks, reaching 4.45%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Raymond James Finl's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.61%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Raymond James Finl's debt-to-equity ratio is below the industry average at 0.28, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Significance of Analyst Ratings Explained</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing Raymond James Finl: Insights From 7 Financial Analysts

Craig-Hallum analyst William Bonello maintained a Buy rating on Biodesix (BDSX – Research Report) today. The company's shares closed last Friday at...

Biodesix (BDSX) Receives a Buy from Craig-Hallum

Biodesix GAAP EPS of -$0.08 beats by $0.01, revenue of $17.9M beats by $1.76M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Biodesix (NASDAQ:<a href="https://investorplace.com/stock-quotes/bdsx-stock-quote/">BDSX</a>) just reported results for the second quarter of 2024.<ul><li>Biodesix reported earnings per share of -8 cents. This was above the analyst estimate for EPS of -9 cents.</li><li>The company reported revenue of $17.93 million.</li><li>This was 10.58% better than the analyst estimate for revenue of $16.21 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/bdsx-stock-earnings-biodesix-for-q2-of-2024/">BDSX Stock Earnings: Biodesix Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

BDSX Stock Earnings: Biodesix Beats EPS, Beats Revenue for Q2 2024

Biodesix, Inc. (BDSX) Q2 2024 Earnings Call Transcript

Canaccord Genuity analyst Kyle Mikson CFA has maintained their bullish stance on BDSX stock, giving a Buy rating yesterday. Kyle Mikson CFA's ratin...

Buy Rating on Biodesix Affirmed Following Strong Q2 Performance and Positive Growth Indicators

Thomas Flaten, an analyst from Lake Street, maintained the Buy rating on Biodesix (BDSX – Research Report). The associated price target remains the...

Strong Sales Growth and Market Position Justify Buy Rating for Biodesix

Daniel Brennan, an analyst from TD Cowen, maintained the Buy rating on Biodesix (BDSX – Research Report). The associated price target was raised to...

Buy Rating Justified: Biodesix's Strong Q2 Performance and Growth Prospects

The latest update is out from Biodesix (BDSX). Biodesix has updated their corporate presentation, now accessible on the Investor Relations section ...

Biodesix Releases Updated Corporate Presentation Information

Lake Street analyst Thomas Flaten maintained a Buy rating on Biodesix (BDSX – Research Report) today and set a price target of $3.00. The company's...

Lake Street Sticks to Its Buy Rating for Biodesix (BDSX)

In a report released today, William Bonello from Craig-Hallum reiterated a Buy rating on Biodesix (BDSX – Research Report), with a price target of ...

Craig-Hallum Keeps Their Buy Rating on Biodesix (BDSX)

BDSX

Press Releases

Biodesix to Report First Quarter 2024 Financial Results on May 8, 2024

Biodesix to Participate in the 2024 RBCCM Global Healthcare Conference

Biodesix Announces First Quarter 2024 Results Driven by Growth in Lung Diagnostic Testing for Lung Nodule Management

Biodesix to Present New Data on the Nodify XL2® Test at ATS 2024 Annual Meeting

Biodesix to Participate in Two Investor Conferences in June

Biodesix Named to Inc. Magazine's 2024 "Best Workplaces"

Biodesix to Report Second Quarter 2024 Financial Results on August 7, 2024

Biodesix to Present at Canaccord Genuity's 44th Annual Growth Conference

Biodesix Announces Second Quarter 2024 Results and Highlights

Biodesix to Present at Two Investor Conferences in September

Accolade

AirSculpt Technologies, Inc. - Common Stock

AirSculpt Technologies

American Shared Hospital Services Common Stock

American Shared Hospital

ATI Physical Therapy, Inc. Class A Common Stock

ATI Physical Therapy

Cryo-Cell International, Inc. Common Stock

Cryo-Cell International

Concord Medical Services Holdings Limited American Depositary Shares (Each represents thirty (30) Class A ordinary shares)

Concord Medical Services

Cross Country Healthcare, Inc. - Common Stock

Cross Country Healthcare

Castle Biosciences

DocGo

Enhabit

Enzo Biochem, Inc. Common Stock ($0.01 Par Value)

Enzo Biochem

Euda Health Holdings Limited - Ordinary Shares

EUDA Health Holdings

Fulgent Genetics

InnovAge Holding

23andMe Holding

Mobile-health Network Solutions - Class A Ordinary Shares

Mobile-health Network

ModivCare

National Research Corporation - Common Stock

National Research

Nutex Health

Performant Financial Corporation - Common Stock

Performant Finl

P3 Health Partners Inc. - Class A Common Stock

P3 Health Partners

Psychemedics

Prenetics Global Limited - Class A Ordinary Share

Prenetics Global

SHL Telemedicine Ltd - American Depositary Shares

Comments

Biodesix

Noticias

Últimas noticias sobre Biodesix (NASDAQ:BDSX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL